These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 31778325)
1. Detection, prediction, and prognosis: blood circulating microRNA as novel molecular markers of head and neck cancer patients. Powrózek T; Porgador A; Małecka-Massalska T Expert Rev Mol Diagn; 2020 Jan; 20(1):31-39. PubMed ID: 31778325 [No Abstract] [Full Text] [Related]
2. Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. Lamichhane SR; Thachil T; Gee H; Milic N Dis Markers; 2019; 2019():8632018. PubMed ID: 31827646 [TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives. Movahedpour A; Ahmadi N; Ghasemi Y; Savardashtaki A; Shabaninejad Z J Cell Biochem; 2019 Oct; 120(10):16316-16329. PubMed ID: 31257636 [TBL] [Abstract][Full Text] [Related]
4. Circulating exosomal miRNAs: clinical significance in human cancers. Avgeris M; Panoutsopoulou K; Papadimitriou MA; Scorilas A Expert Rev Mol Diagn; 2019 Nov; 19(11):979-995. PubMed ID: 31594418 [No Abstract] [Full Text] [Related]
5. Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. Carpi S; Polini B; Fogli S; Podestà A; Ylösmäki E; Cerullo V; Romanini A; Nieri P Expert Rev Mol Diagn; 2020 Jan; 20(1):19-30. PubMed ID: 31747311 [No Abstract] [Full Text] [Related]
6. Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring. Diez-Fraile A; Ceulaer J; Derpoorter C; Spaas C; Backer T; Lamoral P; Abeloos J; Lammens T Cells; 2020 Dec; 10(1):. PubMed ID: 33396240 [TBL] [Abstract][Full Text] [Related]
7. Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium. Pastorino R; Sassano M; Danilo Tiziano F; Giraldi L; Amore R; Arzani D; Abiusi E; Ahrens W; Vilches LA; Canova C; Healy CM; Holcatova I; Lagiou P; Polesel J; Popovic M; Nygård S; Cadoni G; Znaor A; Boffetta P; Matsuo K; Oze I; Brennan P; Boccia S Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2237-2243. PubMed ID: 36126276 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Poel D; Buffart TE; Oosterling-Jansen J; Verheul HM; Voortman J Exp Mol Med; 2018 Mar; 50(3):e454. PubMed ID: 29520111 [TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Hou B; Ishinaga H; Midorikawa K; Shah SA; Nakamura S; Hiraku Y; Oikawa S; Murata M; Takeuchi K Cancer Biol Ther; 2015; 16(7):1042-6. PubMed ID: 25950115 [TBL] [Abstract][Full Text] [Related]
11. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Mohammadi M; Goodarzi M; Jaafari MR; Mirzaei HR; Mirzaei H Cancer Gene Ther; 2016 Nov; 23(11):371-372. PubMed ID: 27740613 [TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs in head and neck cancer: a scoping review of methods. Dharmawardana N; Ooi EH; Woods C; Hussey D Clin Exp Metastasis; 2019 Jun; 36(3):291-302. PubMed ID: 30877500 [TBL] [Abstract][Full Text] [Related]
13. Salivary protein biomarkers for head and neck cancer. Amenábar JM; Da Silva BM; Punyadeera C Expert Rev Mol Diagn; 2020 Mar; 20(3):305-313. PubMed ID: 31986927 [No Abstract] [Full Text] [Related]
14. Circulating MicroRNAs as Potential Biomarkers for Lung Cancer. Müller S; Janke F; Dietz S; Sültmann H Recent Results Cancer Res; 2020; 215():299-318. PubMed ID: 31605236 [TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs as biomarkers in cancer diagnosis. Sohel MMH Life Sci; 2020 May; 248():117473. PubMed ID: 32114007 [TBL] [Abstract][Full Text] [Related]
16. Identification of microRNAs as diagnostic biomarkers in screening of head and neck cancer: a meta-analysis. Zhang M; Zhao LJ; Liang WQ; Mao ZP Genet Mol Res; 2015 Dec; 14(4):16562-76. PubMed ID: 26681002 [TBL] [Abstract][Full Text] [Related]
17. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719 [TBL] [Abstract][Full Text] [Related]
18. Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs. Thomaidou AC; Batsaki P; Adamaki M; Goulielmaki M; Baxevanis CN; Zoumpourlis V; Fortis SP Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897831 [TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients. Yan Y; Wang X; Venø MT; Bakholdt V; Sørensen JA; Krogdahl A; Sun Z; Gao S; Kjems J Oncotarget; 2017 Jan; 8(5):8206-8214. PubMed ID: 28030794 [TBL] [Abstract][Full Text] [Related]
20. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers. Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]